全文获取类型
收费全文 | 757篇 |
免费 | 60篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 22篇 |
妇产科学 | 30篇 |
基础医学 | 70篇 |
口腔科学 | 26篇 |
临床医学 | 57篇 |
内科学 | 154篇 |
皮肤病学 | 59篇 |
神经病学 | 30篇 |
特种医学 | 48篇 |
外国民族医学 | 1篇 |
外科学 | 61篇 |
综合类 | 7篇 |
一般理论 | 3篇 |
预防医学 | 68篇 |
眼科学 | 24篇 |
药学 | 81篇 |
中国医学 | 1篇 |
肿瘤学 | 71篇 |
出版年
2024年 | 2篇 |
2023年 | 7篇 |
2022年 | 39篇 |
2021年 | 60篇 |
2020年 | 38篇 |
2019年 | 42篇 |
2018年 | 62篇 |
2017年 | 35篇 |
2016年 | 54篇 |
2015年 | 35篇 |
2014年 | 55篇 |
2013年 | 55篇 |
2012年 | 76篇 |
2011年 | 58篇 |
2010年 | 37篇 |
2009年 | 31篇 |
2008年 | 37篇 |
2007年 | 22篇 |
2006年 | 21篇 |
2005年 | 20篇 |
2004年 | 10篇 |
2003年 | 9篇 |
2002年 | 12篇 |
2001年 | 1篇 |
2000年 | 1篇 |
1999年 | 1篇 |
1991年 | 1篇 |
1987年 | 1篇 |
排序方式: 共有822条查询结果,搜索用时 22 毫秒
1.
Rania M Seliem Jonathan K Freeman Richard H Steingart Robert P Hasserjian 《Applied immunohistochemistry & molecular morphology》2006,14(1):18-23
Rituximab is a chimeric monoclonal antibody that recognizes the CD20 antigen and is used to treat B-cell non-Hodgkin lymphoma (B-NHL). Few studies have been published examining the use of antibody panels to evaluate B-NHL treated with rituximab. The authors performed a retrospective analysis of immunophenotypic changes and clinical outcome in 18 patients with B-NHL following rituximab therapy. The intensity of CD20 expression was evaluated by flow cytometry and/or immunohistochemistry, before and after rituximab therapy; the latter samples were taken 5 to 12 months after initiating rituximab therapy (median 7 months). Nine of the 18 patients (50%) achieved complete or partial clinical remission and did not have morphologic evidence of lymphoma in the post-therapy samples. The other nine patients (50%) had persistent disease. Two patterns of CD20 expression were noted in the post-therapy samples: unchanged expression of CD20 in neoplastic cells (4/9 cases) and loss of or a significant decrease in detected CD20 expression in neoplastic cells (5/9 cases). These results show that in many cases of B-NHL persisting after rituximab therapy, CD20 expression decreases or is lost, raising the possibility of deletion or expression modulation of the CD20 gene in neoplastic cells. This study also underscores the importance of using a panel of antibodies to evaluate rituximab-treated B-NHL. 相似文献
2.
Pande Apurva Lamba Nayan Mammi Marco Gebrehiwet Paulos Trenary Alyssa Doucette Joanne Papatheodorou Stefania Bunevicius Adomas Smith Timothy R. Mekary Rania A. 《Neurosurgical review》2021,44(3):1227-1241
Neurosurgical Review - Treatment options for hydrocephalus include endoscopic third ventriculostomy (ETV) and ventriculoperitoneal shunt (VPS). Some ambiguity remains regarding indications, safety,... 相似文献
3.
Rania El Fekih James Hurley Vasisht Tadigotla Areej Alghamdi Anand Srivastava Christine Coticchia John Choi Hazim Allos Karim Yatim Juliano Alhaddad Siawosh Eskandari Philip Chu Albana B. Mihali Isadora T. Lape Mauricio P. Lima Filho Bruno T. Aoyama Anil Chandraker Kassem Safa James F. Markmann Leonardo V. Riella Richard N. Formica Johan Skog Jamil R. Azzi 《Journal of the American Society of Nephrology : JASN》2021,32(4):994
BackgroundDeveloping a noninvasive clinical test to accurately diagnose kidney allograft rejection is critical to improve allograft outcomes. Urinary exosomes, tiny vesicles released into the urine that carry parent cells’ proteins and nucleic acids, reflect the biologic function of the parent cells within the kidney, including immune cells. Their stability in urine makes them a potentially powerful tool for liquid biopsy and a noninvasive diagnostic biomarker for kidney-transplant rejection.MethodsUsing 192 of 220 urine samples with matched biopsy samples from 175 patients who underwent a clinically indicated kidney-transplant biopsy, we isolated urinary exosomal mRNAs and developed rejection signatures on the basis of differential gene expression. We used crossvalidation to assess the performance of the signatures on multiple data subsets.ResultsAn exosomal mRNA signature discriminated between biopsy samples from patients with all-cause rejection and those with no rejection, yielding an area under the curve (AUC) of 0.93 (95% CI, 0.87 to 0.98), which is significantly better than the current standard of care (increase in eGFR AUC of 0.57; 95% CI, 0.49 to 0.65). The exosome-based signature’s negative predictive value was 93.3% and its positive predictive value was 86.2%. Using the same approach, we identified an additional gene signature that discriminated patients with T cell–mediated rejection from those with antibody-mediated rejection (with an AUC of 0.87; 95% CI, 0.76 to 0.97). This signature’s negative predictive value was 90.6% and its positive predictive value was 77.8%.ConclusionsOur findings show that mRNA signatures derived from urinary exosomes represent a powerful and noninvasive tool to screen for kidney allograft rejection. This finding has the potential to assist clinicians in therapeutic decision making. 相似文献
4.
5.
6.
7.
8.
9.
10.